Tunisia

Reimbursed Care Access

Tunisia maintains a strict national narcotics law (Loi n°92‑52 du 18 mai 1992) that broadly outlaws cultivation, possession, trafficking and commercial operations involving narcotic plants and controlled psychotropic substances while allowing narrow exceptions for medicine, veterinary use, pharmacy and authorised scientific research. In practice, classic psychedelic compounds (psilocybin, MDMA, DMT, 5‑MeO‑DMT, mescaline, 2C‑X, ayahuasca, ibogaine) have no authorised medical use outside approved research and are treated as strictly controlled; ketamine is routinely used and documented in Tunisian medical practice as an anaesthetic/analgesic, but esketamine (Spravato) has no readily available national marketing authorisation or public reimbursement pathway. All statements about prohibition and research/medical exceptions reference the Tunisian narcotics law and Tunisian clinical literature where noted. [https://www.unodc.org/cld/en/legislation/tun/loi_n_92-52_du_18_mai_1992_relative_aux_stupefiants/chapitre_i/article_2/loi_no._92-52.html|UNODC — Loi n°92-52 du 18 mai 1992]